Methods	Six-week randomised, double-blind study.
Participants	Outpatients fulfilling DSM-III-R criteria for major depressive disorder, with a score of at least 18 on the first 17 items of the HDRS-21. Age range: 65-85 years old. Exclusion criteria: severe physical illness, senile dementia, schizophrenia, organic brain syndrome, alcohol abuse, ECT during the previous 3 months, MAOI in the previous 2 weeks, depot neuroleptics in the previous 4 weeks, oral neuroleptics in the previous 2 weeks
Interventions	Fluoxetine: 52 participants. Paroxetine: 54 participants. Fluoxetine dose range: 20-60 mg/day. Paroxetine dose range: 20-40 mg/day. Temazepam (15-30 mg) was allowed for sleep.
Outcomes	Hamilton Rating Scale for Depression (HDRS-21), MADRS, CGI, MMSE, SCAG
Notes	Funding: by industry
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear